SCHEMBL4490720

SCHEMBL4490720

CC1CC(=O)N(N)C(=O)N1Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.46
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 1/20 0.44
ALOX12 P18054 1/20 0.44
MAPK1 P28482 1/20 0.44
SMO Q99835 2/20 0.42
BRD4 O60885 1/20 0.42
F2 P00734 1/20 0.41
PLG P00747 1/20 0.41
ELANE P08246 1/20 0.41
CTSG P08311 1/20 0.41
CMA1 P23946 1/20 0.41
CTRC Q99895 1/20 0.41
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21538655 0.84 LMNA (0.50) EHMT2KMT2AMEN1LMNAALOX12
SCHEMBL7761783 0.72 LMNA (0.46) EHMT2KMT2AMEN1LMNAALOX12
SCHEMBL19370604 0.72 LMNA (0.52) EHMT2LMNAALOX12MAPK1BRD4
SCHEMBL19468800 0.72 GSK3A (0.50) EHMT2KMT2AMEN1LMNAALOX12
SCHEMBL17793378 0.72 GSK3A (0.50) EHMT2KMT2AMEN1LMNAALOX12
SCHEMBL7407552 0.71 HCRTR2 (0.50) EHMT2KMT2AMEN1BRD4HCRTR1
SCHEMBL2265479 0.71 HCRTR2 (0.50) EHMT2KMT2AMEN1BRD4HCRTR1
SCHEMBL21538562 0.71 CACNA1G (0.50) KMT2AMEN1MAPK1HCRTR1HCRTR2
SCHEMBL18772595 0.70 EHMT2 (0.46) EHMT2KMT2AMEN1LMNAALOX12
SCHEMBL21538635 0.69 ALDH1A1 (0.50) EHMT2KMT2AMEN1F2PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501429-B2 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents QUEEN'S UNIVERSITY AT KINGSTON (CA) 2009-03-10 US disclosed
US-7501429-B2 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents QUEEN'S UNIVERSITY AT KINGSTON (CA) 2009-03-10 US disclosed
US-7501429-B2 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents QUEEN'S UNIVERSITY AT KINGSTON (CA) 2009-03-10 US disclosed
US-20030153584-A1 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents QUEEN'S UNIVERSITY (CA) 2003-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153584-A1 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents NUDT1, DPYD, TYMP EHMT2 1259/4885KMT2A 1914/4885MEN1 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.